Storia in 2 fonti

This Summit Therapeutics Analyst Is No Longer Bullish; Here Are Top 2 Downgrades For Friday - Centene (NY

Analysts changed outlook on top names, including SMMT, DAVA. See what others think before buying SMMT stock.

Raccontata da

Confronto fonti

2 prospettive sulla stessa storia

AI · summaries

benzinga.comStai leggendo3 mesi fa

Analysts changed outlook on top names, including SMMT, DAVA. See what others think before buying SMMT stock.

Bernstein analyst Jeffrey Walch initiated coverage of Summit Therapeutics (SMMT) with an Underperform rating and $7.70 price target The firm re...